E
Ernexa Therapeutics Inc. (ERNA)
NCM – Real vaqt narxi. Valyuta: USD
12.01
+4.80 (66.57%)
Yopilishda: May 12, 2026, 4:00 PM EDT
12.10
+0.09 (0.75%)
Bozor oldidan: May 13, 2026, 5:07 AM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
Find any stock by ticker or company name
NCM – Real vaqt narxi. Valyuta: USD
12.01
+4.80 (66.57%)
Yopilishda: May 12, 2026, 4:00 PM EDT
12.10
+0.09 (0.75%)
Bozor oldidan: May 13, 2026, 5:07 AM EDT
Ernexa Therapeutics Inc., preclinical bosqichdagi kompaniya, saraton va otoimmün kasalliklarni davolash uchun induksiyalangan mezenximal ildiz hujayralari (iMSC) asosidagi terapiyalarni ishlab chiqadi. Kompaniyaning asosiy mahsuloti ERNA-101 bo'lib, bu tuxumdon saratonini davolash uchun allogenik, yallig'lanishga qarshi sitokin (IL-7/IL-15) ajratuvchi iMSC; va ERNA-201, revmatoid artritni davolash uchun yallig'lanishga qarshi sitokin (IL-10) ajratuvchi iMSC. Kompaniyaning Factor Bioscience Limited bilan litsenzion kelishuvi mavjud. Kompaniya ilgari Eterna Therapeutics Inc. nomi bilan tanilgan va 2025 yil mart oyida Ernexa Therapeutics nomini o'zgartirgan. Ernexa Therapeutics Inc. 2018 yilda tashkil etilgan va Kembrij, Massachusetsda joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. Kanika Chawla Ph.D. | Senior Vice President of Technical Operations (Consultant) |
| Dr. Robert Hamilton Pierce M.D. | Chief Scientific Officer |
| Mr. Sanjeev Luther | CEO, President & Director |
| Ms. Dorothy J. Clarke | General Counsel |
| Ms. Sandra M. Gurrola | Senior VP of Finance |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-05-04 | 8-K | form8-k.htm |
| 2026-04-13 | DEF 14C | formdef14c.htm |
| 2026-04-01 | PRE 14C | formpre14c.htm |
| 2026-03-26 | CORRESP | filename1.htm |
| 2026-03-24 | S-3/A | forms-3a.htm |
| 2026-03-20 | 8-K | form8-k.htm |
| 2026-03-16 | S-3 | forms-3.htm |
| 2026-03-13 | 10-K | form10-k.htm |
| 2026-02-26 | 8-K | form8-k.htm |
| 2026-02-11 | 8-K | form8-k.htm |